Blood test could personalize lung cancer care
NCT ID NCT04166487
Summary
This study is testing if a simple blood test, taken at different times, can help doctors see how well a patient's advanced lung cancer is responding to an immunotherapy drug called pembrolizumab. Based on the blood test results, doctors will decide if the patient should continue with the immunotherapy alone or add chemotherapy. The goal is to use this information to better control the cancer and tailor treatment for each person.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Dana-Farber at Steward St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135, United States
-
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) in clinical affiliation with South Shore Hospital
South Weymouth, Massachusetts, 02190, United States
Conditions
Explore the condition pages connected to this study.